HCLTECH
11.1.2024 14:05:00 CET | Business Wire | Press release
HCLTech, a leading global technology company, will join forces with key stakeholders from across the globe at the 54th Annual Meeting of the World Economic Forum (WEF) in Davos from Jan. 15–19, 2024. The company will contribute to deliberations on this year’s theme of “Rebuilding Trust” and discovering solutions with transparency, consistency and accountability.
HCLTech will be represented by its Chairperson Roshni Nadar Malhotra, CEO and Managing Director C Vijayakumar, Chief Technology Officer Kalyan Kumar; Chief Growth Officer for Europe and Africa, Ashish Kumar Gupta; President, Digital Foundation Services, Jagadeshwar Gattu; Global Head, Financial Services, Srinivasan Seshadri; Chief Marketing Officer Jill Kouri and Global Head, Sustainability, Santhosh Jayaram.
HCLTech will once again host guests at its pavilion at the iconic Promenade 66 which will be fully powered by locally produced green energy, underscoring the company’s commitment to a sustainable planet. In addition to its differentiated portfolio of services across digital, engineering, cloud, AI and software, HCLTech will showcase its award-winning sustainability solution, Net Intelligent Zero (NIO), at the pavilion with a live data feed.
This year, HCLSoftware makes its WEF debut with a dedicated lounge within the HCLTech pavilion. Chief Revenue Officer Rajiv Shesh and Chief Product Officer Kalyan Kumar will lead the HCLSoftware contingent that will showcase its cutting-edge software solutions that help enterprises navigate digital transformation.
HCLTech will participate in and host a series of panels and sessions on the future of technology, sustainability, diversity and inclusion in line with its brand purpose of bringing together the best of technology and its people to supercharge progress.
- The highlight this year will be the ‘Heroes of Progress’ reception on Jan. 17 to honor WEF Global Shapers who are making significant contributions to the fields of environment, women’s empowerment, art and sustainability.
- Roshni Nadar Malhotra, Chairperson, HCLTech is discussing the global water cycle and the potential of water as an enabler for SDGs on a panel on 'Out of Balance with Water' on Jan. 17, 15:00-15:45, Congress Center.
- Srinivasan Seshadri, Chief Growth Officer and Global Head, Financial Services, HCLTech, will lead an affiliate session on ‘Banking on trust through transformative tech’ on Jan. 16, 10:15-11:15 at Dome C, Ice Village.
- HCLTech is conducting broadcast sessions at its pavilion on Jan. 16, 17 and 18, 13:00–13:45. Dr. Saikat Chaudhuri, Innovation, Strategy and Engineering Professor, UC Berkeley will be moderating all three sessions with key industry leaders on: technology-led disruption, opportunities and impact; diversity-led progress for the future workforce; purpose-led sustainability agenda.
Additionally, HCL Group and Uplink, the open innovation platform of WEF, will announce the winners of this year’s Aquapreneur Challenge as part of their ongoing partnership.
To learn more about HCLTech@WEF 2024 visit World Economic Forum (WEF) 2024 at Davos | HCLTech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111423911/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom